KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Change in Accured Expenses for 16 consecutive years, with -$174.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 181.54% year-over-year to -$174.9 million, compared with a TTM value of $75.1 million through Dec 2025, down 17.59%, and an annual FY2025 reading of $75.1 million, down 17.59% over the prior year.
  • Change in Accured Expenses was -$174.9 million for Q4 2025 at Alnylam Pharmaceuticals, down from $223.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $223.5 million in Q3 2025 and bottomed at -$174.9 million in Q4 2025.
  • Average Change in Accured Expenses over 5 years is $26.4 million, with a median of $57.3 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses surged 324.26% in 2021, then tumbled 3101.17% in 2025.
  • Year by year, Change in Accured Expenses stood at $39.5 million in 2021, then soared by 159.78% to $102.6 million in 2022, then plummeted by 137.68% to -$38.7 million in 2023, then crashed by 60.62% to -$62.1 million in 2024, then crashed by 181.54% to -$174.9 million in 2025.
  • Business Quant data shows Change in Accured Expenses for ALNY at -$174.9 million in Q4 2025, $223.5 million in Q3 2025, and $182.1 million in Q2 2025.